MV BioTherapeutics SA

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) increases anti-tumor immunity by blocking molecules that suppress anti-tumor activity and has provided unprecedented curative response in patients with solid tumors. However, only a limited fraction of patients benefits from the therapeutic response obtained with these biologic drugs. Antitumor immunity by ICIs is conditioned by the intestinal microbiota and several studies have shown that manipulating the microbiota may positively affect cancer immunotherapy outcome. In fact, the success of immunotherapy is connected to the composition of a human patient’s gut microbiome. Our lead product, MV004, promotes gut adaptation to ICIs and expansion of tumoricidal cells in the terminal ileum that significantly improve ICIs efficacy.